At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 40 enrolled

Drug / intervention

Velcade/Dexamethasonedrug

Likely dose

Velcade/Dexamethasone 1,3 mg/m2from record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00391157

NCT00391157Phase 2Completed

VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients.

PETHEMA Foundation·interventional·Posted Oct 23, 2006·Updated Sep 18, 2009

In Brief

A Phase 2 clinical trial evaluating Velcade/Dexamethasone for Multiple Myeloma. Completed, enrolled 40 participants across 10 sites.

The primary efficacy objective of this study is to study the efficacy in terms of response rate to alternating bortezomib/dexamethasone regimen

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesSpain

Collaborators--

Phase 2CompletedFinished

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartAug 2005

First PostedOct 2006

Primary CompletionJun 2007

Study CompletionJan 2008

TodayJul 2026

First PostedOct 23, 2006

Enrollment StartAug 1, 2005

Primary CompletionJun 1, 2007

Study CompletionJan 1, 2008

TodayJul 2, 2026

Enrollment to primary: 1.8 yearsPosted 19.7 years ago

Velcade/Dexamethasonedrug

Velcade 1,3 mg/m2 on days 1, 4, 8 and 11